Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; 5 of the 8 sources its claims cite were checked for support.
Abstract
Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is the second leading cause of cancer mortality worldwide. Fibroblast Growth Factor 19 (FGF19) is one of the most frequently amplified genes in HCC patients. Moreover, mice expressing an FGF19 transgene have been shown to develop HCC. However, the downstream signalling pathways that mediate FGF19-dependent tumorigenesis remain to be deciphered. Here we show that FGF19 triggers a previously unsuspected, non-cell-autonomous program to activate STAT3 signalling in hepatocytes through IL-6 produced in the liver microenvironment. We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact. Collectively, these data reveal a key role for the IL-6/STAT3 axis in potentiating FGF19-driven HCC in mice, a finding which may have translational relevance in HCC pathogenesis.
Overview
CoChat Summary
TL;DR
FGF19-driven hepatocellular carcinogenesis in mice requires non-cell-autonomous IL-6/STAT3 signaling: FGF19 induces IL-6 from liver innate immune cells, which activates STAT3 in hepatocytes to promote tumorigenesis. Blocking this axis prevents FGF19-induced HCC while preserving FGF19’s bile acid, glucose, and energy metabolic functions.
Key findings
- Hepatocyte-specific Stat3 deletion blocked FGF19-induced HCC: ∼90% of Stat3f/f mice developed hepatocellular carcinomas 12 months after AAV-FGF19, whereas tumor incidence, multiplicity, and size were markedly reduced in Stat3ΔHep mice; serum FGF19 was 292±29 ng ml−1 in Stat3f/f and 275±47 ng ml−1 in Stat3ΔHep mice.
- Stat3 was dispensable for FGF19 metabolic actions: FGF19 reduced Cyp7a1 mRNA by 77% in Stat3f/f and 87% in Stat3ΔHep mice, and Cyp8b1 by 95% and 88%, respectively; body weight, glucose, body composition, and steatosis effects were similar.
- FGF19 activated STAT3 non-cell-autonomously via IL-6: FGF19 induced hepatic pSTAT3Y705 in vivo but not in isolated mouse or human hepatocytes; IL-6 mRNA increased in FGF19-treated db/db mice, and IL-6 was produced mainly by CD45+ myeloid cells including Kupffer cells, neutrophils, and NK cells.
- Genetic or pharmacological blockade of IL-6/STAT3 abolished FGF19-driven HCC: Il6 deletion reduced tumor multiplicity, size, and glutamine synthetase-positive tumor area; SOCS3 co-expression, tofacitinib, or anti-IL-6 treatment reduced or abolished tumors without altering FGF19 metabolic effects. In human data, FGF19 amplification occurred in 7% of HCCs, and FGF19 mRNA was elevated in 10/83 FFPE HCC specimens (12%), all co-overexpressing BIRC5.
Methods
- Mouse models: AAV-FGF19 delivery in Stat3f/f, hepatocyte-specific Stat3ΔHep, Il6−/−, db/db, and Mdr2−/− mice; primary mouse and human hepatocytes; immune cell depletion with clodronate liposomes or antibodies.
- Main assays: immunoblotting for pSTAT3/pERK, qRT-PCR, immunohistochemistry, flow cytometry, BrdU incorporation, ELISA for FGF19/insulin/liver enzymes/bile acids, and tumor assessment by gross and histological analysis.
- Human data and statistics: TCGA and GTEx bioinformatics, RNAscope in situ hybridization and qRT-PCR on human HCC samples; unpaired t-test, one-way ANOVA with Dunnett’s post-test, Spearman correlation, and Kaplan–Meier log-rank analysis.
Limitations
- Stated: the extent to which mouse findings translate to human HCC remains unclear; other mechanisms of FGF19 tumorigenesis are not excluded; the precise mechanism by which FGF19 promotes IL-6 secretion from innate immune cells remains to be determined; direct effects of IL-6 on stem-marker-enriched hepatocyte subpopulations were not observed and require further study.
- Evident: investigators were not blinded during the studies; in vivo experiments used cohorts of 3–9 mice per group; male mice were used unless otherwise specified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
4 Valid · 0 Not valid · 0 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In defining a central role for STAT3 in FGF19-driven hepatocarcinogenesis, the data presented in this report extend previous findings on the causal role played by STAT3 in hepatocellular tumorigenesis4445, and suggest that STAT3 may serve as a common signalling node in the development of HCC associated with diverse etiologies, including viral infection, and metabolic and hormonal dysregulation.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Discussion
What the sources say
- Supportedcites [44] He, G. et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286–297 (2010). source
The citation is attached to the preceding statement about STAT3’s causal role in hepatocellular tumorigenesis, not to the citing authors’ subsequent suggestion about diverse etiologies. In Results (‘STAT3 activity is required for HCC formation and growth’), hepatocyte-specific STAT3-deficient mice had markedly fewer and smaller DEN-induced tumors, supporting that attributed finding. (LLM, conf=0.92)
- Supportedcites [45] Bard-Chapeau, E. A. et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629–639 (2011). source
The Results section reports that Stat3 deletion abolished the increase in HCC development caused by Shp2 deletion, supporting the cited claim of a causal role in hepatocellular tumorigenesis. The Discussion also notes that Stat3 was not required for HCC development in the DEN-induced model. The broader proposal about diverse etiologies is the citing authors’ own suggestion, not a finding attributed to this source; page numbers were not supplied. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, FGF19 administration failed to induce hepatic expression of a panel of growth factors and cytokines associated with increased pSTAT3 signalling, including epidermal growth factor (EGF)31, IL-10 (ref. 32), IL-21 (ref. 33), IL-22 (ref. 34) and IL-31 (ref. 35)”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Results > Secreted factor(s) mediating activation of STAT3 by FGF19
What the sources say
- Not checked — no full text of the sourcecites [31] Zhong, Z., Wen, Z. & Darnell, J. E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95–98 (1994). source
- Supportedcites [32] Weber-Nordt, R. M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954–27961 (1996). source
Reference 32 is attached to IL-10 as an example of a cytokine associated with increased pSTAT3 signalling, not to the citing authors’ finding about FGF19 or hepatic expression. The Results section reports that adding IL-10 generated tyrosine-phosphorylated Stat3; it does not need to establish the separate FGF19 finding. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [33] Brenne, A. T. et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99, 3756–3762 (2002). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Notably, IL-6 appears to be an essential factor common to the induction of HCC by a variety of stimuli, including chemical61, obesity62 and FGF19.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Discussion
What the sources say
- Not checked — no full text of the sourcecites [61] Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121–124 (2007). source
- Supportedcites [62] Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010). source
Citation 62 is attached to obesity, not to chemical induction or FGF19. In Results, “Enhanced IL-6 production is required for obesity-induced tumor promotion,” IL6-deficient male mice showed no significant increase in tumor load with a high-fat diet, supporting the attributed role of IL-6 in obesity-promoted HCC in this mouse model. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.”
- Also stated in: § Stat3 is essential for FGF19-induced hepatocarcinogenesis · boosted
“Collectively, we conclude from these observations that hepatocellular ablation of Stat3 blocks the initiation and progression of FGF19-dependent HCC formation.”
- Also stated in: § Discussion · plain
“Our results showed that hepatocellular STAT3 is a critical effector in FGF19-induced HCC formation.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Abstract
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Stat3 is essential for FGF19-induced hepatocarcinogenesis · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.”
- Also stated in: § Stat3 is dispensable for FGF19-regulated metabolism · plain
“Therefore, while critical for FGF19-dependent HCC formation, hepatocellular Stat3 is not required for FGF19 to regulate bile acid biosynthesis or restore metabolic homoeostasis.”
§ Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Stat3 is dispensable for FGF19-regulated metabolism · plain
46 more claims
Create a free account to see all 79 claims and every source verdict.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been found that the tumorigenic effect of FGF19 is mediated by the release of interleukin 6 (IL6) by Kupffer cells that activate the signal transducer and activator of transcription (STAT3) pathway in hepatocytes [261].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [261]
In the citing paper
“NGM282 is a nontumorigenic analogue of FGF19 being evaluated for the treatment of PBC.”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [16]
In the citing paper
“In contrast, NGM282 does not activate STAT3, a signaling pathway essential for FGF19‐mediated hepatocarcinogenesis.16”
From NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2018) · cites this paper as [16]
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Cited by
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Pierantonelli, I., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 460
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425
Self-citationLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280
Self-citationHarrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262
“NGM282 is an engineered analogue of FGF19 that potently inhibits de novo bile acid synthesis while eliminating FGF19-associated tumorigenicity.(9,10) Preclinical studies have demonstrated that NGM282 impacts multiple pathways relevant to NASH pathogenesis by inhibiting de novo lipogenesis, improving insulin sensitivit…”
BackgroundSelf-citationBile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Zhang, X., Hu, F., Li, G., Li, G., Yang, X., Liu, L., Zhang, R., Zhang, B., & Feng, Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0176-3 · Cited by 243
Xie, M., Lin, Z., Ji, X., Luo, X., Zhang, Z., Sun, M., Chen, X., Zhang, B., Liang, H., Liu, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.036 · Cited by 212
Ma, H., Wang, J., Zhao, X., Wu, T., Huang, Z., Chen, D., Liu, Y., & Ouyang, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.075 · Cited by 196
Hirschfield, G. M., Chazouillères, O., Drenth, J. P., Thorburn, D., Harrison, S. A., Landis, C. S., Mayo, M. J., Muir, A. J., Trotter, J. F., Leeming, D. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.035 · Cited by 187
“Most common (>10%) adverse events, n (%) Injection site reactions 1 (5) 2 (10) 11 (52)”
BackgroundInfluentialSelf-citationHarrison, S. A., Rolph, T., Knott, M., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.034 · Cited by 168
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Castelli, G., Pelosi, E., & Testa, U. (2017) · Cancers · doi:10.3390/cancers9090127 · Cited by 158
Radharani, N. N. V., Yadav, A. S., Nimma, R., Kumar, T. V. S., Bulbule, A., Chanukuppa, V., Kumar, D., Patnaik, S., Rapole, S., & Kundu, G. C. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02527-9 · Cited by 174
Zhou, M., Learned, R. M., Rossi, S. J., DePaoli, A. M., Tian, H., & Ling, L. (2017) · Hepatology Communications · doi:10.1002/hep4.1108 · Cited by 152
Self-citationNew developments in the biology of fibroblast growth factors
Ornitz, D. M., & Itoh, N. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1549 · Cited by 144
Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00935-7 · Cited by 139
Mayo, M. J., Wigg, A. J., Leggett, B. A., Arnold, H., Thompson, A. J., Weltman, M., Carey, E. J., Muir, A. J., Ling, L., Rossi, S. J., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1209 · Cited by 125
“(15) In contrast, NGM282 does not activate STAT3, a signaling pathway essential for FGF19-mediated hepatocarcinogenesis.(16) In animal models of cholestasis and cholangiopathy, NGM282 inhibited bile acid synthesis, reduced excess hepatic bile acid accumulation, and protected mice from liver injury induced by intrahepa…”
BackgroundSelf-citationThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Somm, E., & Jornayvaz, F. R. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00134 · Cited by 116
Ma, Y., Huang, T., Zhong, X., Zhang, H., Cong, X., Xu, H. W., Lu, G., Yu, F., Xue, S., Lv, Z., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0890-1 · Cited by 112
Henriksson, E., & Andersen, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601349 · Cited by 95
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 96
“One of them, NGM282 also referred to as Aldafermin, is a full FGFR4 agonist, but due to its inability to activate STAT3 pathway, it lacks tumor-promoting activity in mice [42,49].”
BackgroundVesterhus, M., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80
Gao, L., Lang, L., Zhao, X., Shay, C., Shull, A. Y., & Teng, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0591-7 · Cited by 87
Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 79
Self-citationFibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Pan, M., Wang, H., Ansari, K. H., Li, X., Sun, W., & Fan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01742-4 · Cited by 82
Wang, Y., Liu, D., Zhang, T., & Xia, L. (2021) · Cancers · doi:10.3390/cancers13061360 · Cited by 80
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761538 · Cited by 76
“Aldafermin (alias NGM282) is an engineered non-carcinogenic FGF19 analog that maintains a key region of the protein involved in receptor interactions and signaling modulation but does not activate the FGF19STAT3 carcinogenic pathway (82, 83).”
BackgroundSong, L., Wang, L., Hou, Y., Zhou, J., Chuchu, C., Ye, X., Dong, W., Gao, H. F., Liu, Y., Qiao, G., et al. (2022) · Hepatology · doi:10.1002/hep.32404 · Cited by 68
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0187 · Cited by 61
“NGM282, an FGF19 analog, inhibits bile acid synthesis without FGF19-related hepatocarcinogenesis.(124,125) In mouse models of NASH, NGM282 exerts anti-steatotic, anti-inflammatory, and antifibrotic effects without promoting liver tumorigenesis.”
BackgroundStruik, D., Dommerholt, M. B., & Jonker, J. W. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000599 · Cited by 61
Miao, X., Xiang, Y., Mao, W., Chen, Y., Li, Q., & Fan, B. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00314.2019 · Cited by 57
The Cancer Stem Cell in Hepatocellular Carcinoma
Schulte, L.-A., López-Gil, J. C., Sáinz, B., & Hermann, P. C. (2020) · Cancers · doi:10.3390/cancers12030684 · Cited by 60
Zhang, X. Y., Soutto, M., Chen, Z., Bhat, N. S., Zhu, S., Eissmann, M. F., Ernst, M., Lu, H., Peng, D., Xu, Z., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.05.016 · Cited by 57
Song, J., Zhang, X., Ge, Q., Yuan, C., Chu, L., Liang, H., Liao, Z., Liu, Q., Zhang, Z., & Zhang, B. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27050 · Cited by 59
Reciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases
Shen, L., Li, Y., & Zhao, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390453 · Cited by 59
“Collectively, macrophage-derived IL-6 signaling plays a pivotal role in potentiating FGF19-driven HCC pathogenesis in mice (94).”
BackgroundMASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Nevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 55
Yoo, C., Kang, J., Lim, H. Y., Kim, J. H., Lee, M. A., Lee, K.-H., Kim, T., & Ryoo, B. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.226 · Cited by 53
Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver
Gadaleta, R. M., & Moschetta, A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.029 · Cited by 48
Solís-Martínez, R., Cancino-Marentes, M., Hernández-Flores, G., Ortiz-Lazareno, P., Mandujano-Álvarez, G., Cruz-Gálvez, C., Sierra-Díaz, E., Rodríguez-Padilla, C., Jave-Suárez, L. F., Aguilar-Lemarroy, A., et al. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.009 · Cited by 47
González-Meljem, J. M., & Martínez-Barberá, J. P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03798-7 · Cited by 53
“FGF signalling has also been implicated in cell non-autonomous tumourigenesis in the liver, as virally-delivered FGF19 or skeletal muscle-derived FGF19 were shown to be required for the induction of hepatocellular carcinomas in mice [128, 129].”
BackgroundMa, H., Yan, D., Wang, Y., Shi, W., Liu, T., Zhao, C., Huo, S., Duan, J., Tao, J., Zhai, M., et al. (2019) · Cancer Science · doi:10.1111/cas.13940 · Cited by 43
Li, F., Li, Z., Han, Q., Cheng, Y., Ji, W., Yang, Y., Lü, S., & Xia, W. (2020) · Oncogene · doi:10.1038/s41388-020-1227-2 · Cited by 48
The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma
Chen, Z., Jiang, L., Liang, L., Koral, K., Zhang, Q., Zhao, L., Lu, S., & Tao, J. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.014 · Cited by 47
“The IL-6/STAT3 axis is involved in FGF19-driven HCC in mice.(30) FGF19 increases IL-6 production in the liver microenvironment followed by STAT3 activation in”
BackgroundA spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD
Younes, R., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0094-6 · Cited by 42
Zhou, Q., Qi, F., Zhou, C., Ji, J., Jiang, J., Wang, C., Zhao, Q., Jin, Y., Wu, J., Cai, Q., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02885-2 · Cited by 48
“Then, an online Venn diagram website(http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to identify the intersecting genes.”
Self-citationCurrent and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39
“The creation of the FGF19 variant, NGM282, prevented this problem, as it does not activate signal transducer and activator of transcription 3 (STAT3) [103].”
BackgroundBeta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies
Hua, S., Liu, Q., Li, J., Fan, M., Yan, K., & Ye, D. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09661-1 · Cited by 40
Zhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 38
“repression of CYP7A1 expression and the STAT3 signaling to promote hepatocarcinogenesis (15, 18, 36).”
BackgroundSelf-citationYang, Y., Wang, W. T., Chang, H., Han, Z., Yu, X., & Zhang, T. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14592 · Cited by 41
Zhang, C., Liu, Y., Wang, Y., Ge, X., Jiao, T., Yin, J., Wang, K., Li, C., Guo, S., Xie, X., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01394 · Cited by 43
Gai, X., Zhou, P., Xu, M. M., Liu, Z., Zheng, X. M., & Liu, Q. (2019) · Journal of Cancer · doi:10.7150/jca.35631 · Cited by 41
“IL-6/STAT3 pathway was also found hyperactivated aberrantly in HCC microenvironment and involved in hepatocarcinogenesis[16-18].”
BackgroundMPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway
Zou, H., Chen, Q., Zhang, A., Wang, S., Wu, H., Yuan, Y., Wang, S., Yu, J., Luo, M., Wen, X., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1324-8 · Cited by 35
Sciarrillo, C. M., Keirns, B. H., Koemel, N. A., Anderson, K. L., & Emerson, S. R. (2021) · Liver International · doi:10.1111/liv.14802 · Cited by 35
Lin, G., Lin, L., Chen, X., Chen, L., Yang, J., Chen, Y., Qian, D., Zeng, Y., & Xu, Y. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06919-9 · Cited by 42
Alvarez-Sola, G., Uriarte, I., Latasa, M. U., Jimenez, M., Barcena-Varela, M., Santamaría, E., Urtasun, R., Rodriguez-Ortigosa, C., Prieto, J., Corrales, F. J., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.480 · Cited by 33
“mechanism of FGF19-mediated IL-6 induction was not examined.(44) In view of these and our current observations, we evaluated the expression of the FGF19 receptors FGFR4, FGFR1c and the obligate co-receptor Klb(45) in murine macrophages.”
BackgroundResultInfluentialFibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 34
“The STAT-3 signaling pathway was activated in the hepatocytes of FGF19 transgenic mice via IL-6, transforming normal hepatocytes into malignant cells [61].”
BackgroundSelf-citationKhan, M. G. M., Ghosh, A., Variya, B. C., Santharam, M. A., Ihsan, A. U., Ramanathan, S., & Ilangumaran, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07285-3 · Cited by 35
Curtailing FGF19’s mitogenicity by suppressing its receptor dimerization ability
Niu, J., Zhao, J., Wu, J., Qiao, G., Gu, J., Zhou, C., Li, Q., Lei, Y., Wang, D., Lin, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010984117 · Cited by 31
“The interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway has been shown to mediate FGF19-driven hepatocarcinogenesis (27).”
BackgroundThe gut–liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19
Piglionica, M., Cariello, M., & Moschetta, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.005 · Cited by 31
MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Maharati, A., Zangouei, A. S., Khalili‐Tanha, G., & Moghbeli, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00840-4 · Cited by 28
Wang, H., Yang, J., Zhang, K., Liu, J., Li, Y., Su, W., & Song, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650388 · Cited by 34
“Non-cellautonomous activation of IL-6/STAT3 signaling is involved in FGF19-driven hepatocarcinogenesis (Zhou et al., 2017).”
BackgroundLaparra, J. M., & Haros, C. M. (2019) · Food & Function · doi:10.1039/c9fo00795d · Cited by 26
Li, P., Li, Q., Biswas, N., Xin, H., Diemer, T., Liu, L., Pérez, L., Paternostro, G., Piermarocchi, C., Domanskyi, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114511 · Cited by 26
Qiu, X., Zhou, J., Xu, H., Li, Y., Ma, S., Qiao, H., Zeng, K., Wang, Q., Ouyang, J., Liu, Y., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.012 · Cited by 29
“6,47 After pentobarbital sodium (50 mg/kg) anesthesia, mice were sacri fi ced by cervical dislocation.”
Chen, S., Tang, Y., Yany, C., Li, K., Huang, X., & Cao, J. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4461 · Cited by 25
“IL-6 binds to glycoprotein 130 and induces Janus kinase phosphorylation, which results in the phosphorylation of Tyr705 in STAT3, the promotion of STAT3 binding to dNA and the activation of certain genes downstream of STAT3 to promote the development of liver cancer (14,15).”
BackgroundThe Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism
Cariello, M., Piglionica, M., Gadaleta, R. M., & Moschetta, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_235 · Cited by 24
Making Way for Suppressing the FGF19/FGFR4 Axis in Cancer
Prieto‐Domínguez, N., Shull, A. Y., & Teng, Y. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0099 · Cited by 22
Zhao, Z., Xiong, S., Wang, R., Li, Y., Wang, X., Wang, Y., Bai, S., Chen, W., Zhao, Y., & Cheng, B. (2019) · Cancer Management and Research · doi:10.2147/cmar.s192263 · Cited by 20
Lin, L., Huang, K., Guo, W., Zhou, C., Wang, G., & Zhao, Q. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa044 · Cited by 22
Williams, C. M., Calderon, J. H., Hock, E., Jimenez, Y., Barringer, K., Carbonaro, M., Molina‐Portela, M. D. P., Thurston, G., Li, Z., & Daly, C. (2021) · The FASEB Journal · doi:10.1096/fj.202002203r · Cited by 19
Andrographolide derivative as STAT3 inhibitor that protects acute liver damage in mice
Chen, S., Feng, L., Ding, M., Wang, D., Zhao, Q., Wang, Y., Zhou, G., & Wang, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.09.002 · Cited by 18
“Constitutive activation of STAT3 promotes fibroblast growth factor 19 (FGF19)-triggered tumorigenesis.(11) Dimerization of STAT3 is critical to control activation and nucleus translocation of STATs.”
BackgroundPresent and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 20
“On the other hand, NGM-282 (a non-tumorigenic variant of FGF19) is a ligand, when bound to which, FGF19 loses its tumorigenic activity [75].”
BackgroundSystematic review of the roles of interleukins in hepatocellular carcinoma
Hu, Y., Xuefeng, Y., & Jianhua, X. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.001 · Cited by 16
Brown, A. R., Alhallak, I., Simmen, R. C. M., Melnyk, S. B., Heard‐Lipsmeyer, M. E., Montales, M. T. E., Habenicht, D., Van, T. T., & Simmen, F. A. (2022) · Cancers · doi:10.3390/cancers14071737 · Cited by 18
“Our observation of a potential linkage between KLF9 and IL-6 is also noteworthy since IL-6 is a known liver mitogen implicated in liver carcinogenesis [63,64].”
BackgroundNuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 17
“Together, these changes enable biased FGF receptor signaling away from STAT3 activation, and this differential downstream signaling is suggested to impart protection from hepatocellular mitogenicity [120].”
BackgroundYang, Y., Yang, L., & Li, Y. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.030 · Cited by 16
Aborehab, N. M., & Waly, N. E. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.05.008 · Cited by 15
“Another study showed that blockage of IL-6 inhibited mice fibroblast growth factor 19 (FGF19) induced hepatocarcinogenesis [44].”
BackgroundZhou, Y., Yang, L., Bo, C., Zhang, X., Zhang, J., & Li, Y. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s290237 · Cited by 19
Chen, X., Sun, Z., Zhou, S., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23552 · Cited by 13
“in the microenvironment, and other complex reasons lead to tumorigenesis.(36,37) Mechanistically, SBK1 expression activated the Nur77/FGF21 pathway to regulate lipid metabolism.”
BackgroundLópez-Pascual, A., Russo-Cabrera, J. S., Ardaiz, N., Palmer, T., Graham, A.-R., Uriarte, I., Gomar, C., Ruiz-Guillamon, D., Latasa, M. U., Arechederra, M., et al. (2024) · Clinical Science · doi:10.1042/cs20241137 · Cited by 15
Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma
Attia, Y. M., Ewida, H. A., & Ahmed, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00008-7 · Cited by 14
Cellular Origin of Hepatocellular Carcinoma
Schneller, D., & Angel, P. E. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019.ch1 · Cited by 19
“Stat3f/f mice, Il6−/− AAV injection db/db mice, Mdr2−/− mice IL-6/STAT3 (49)”
BackgroundYang, L., Yu, X., & Yang, Y. (2018) · Endocrine Connections · doi:10.1530/ec-18-0356 · Cited by 13
Ueda, H., Honda, A., Miyazaki, T., Morishita, Y., Hirayama, T. T., Iwamoto, J., & Ikegami, T. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000606 · Cited by 12
Endocrine FGFs and their signaling in the brain: Relevance for energy homeostasis
Zangerolamo, L., Carvalho, M. U. W. B. D., Velloso, L. A., & Barbosa, H. C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176248 · Cited by 11
Lin, H., Zhou, C., Hou, Y., Li, Q., Qiao, G., Wang, Y., Huang, Z., & Niu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01515 · Cited by 11
FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
Ursic-Bedoya, J., Desandré, G., Chavey, C., Marie, P., Polizzi, A., Rivière, B., Guillou, H., Assenat, E., Hibner, U., & Gregoire, D. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00021-x · Cited by 11
Domfeh, S. A., Narkwa, P. W., Quaye, O., Kusi, K. A., Awandare, G. A., Ansah, C., Salam, A., & Mutocheluh, M. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03326-x · Cited by 10
“The current interventions used in the management of HCC include targeted systemic chemotherapy, liver transplantation, surgical resection, percutaneous radiofrequency ablation, transarterial chemoembolization and radioembolization [22].”
BackgroundInfluentialCellular Origins and Lineage Plasticity in Cancer
Pitarresi, J. R., & Stanger, B. Z. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041389 · Cited by 11
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 11
“Although it has been reported that pharmacologically use of FGF15/19 leads to liver cell growth and neoplasia [128], NGM282, a full FGFR4 agonist, due to its inability to activate STAT3 pathway, it lacks tumor-promoting activity in mice [126, 132].”
BackgroundA short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)
Roberts, S. K., & Majeed, A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1999416 · Cited by 9
NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter
Tabibian, J. H., & Lindor, K. D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.006 · Cited by 7
Zhan, T., Feng, X., Huang, H., Zhan, J.-C., Liu, X.-K., & Cheng, Q. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i9.108649 · Cited by 10
Wu, Y. S., Liu, X., Yu, L., Yan, H., Xie, Y., Pu, Q., Liang, Y., Kong, Y., & Yang, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148526 · Cited by 6
Metadata
- Authors
- Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L.
- Affiliations
- NGM Biopharmaceuticals (United States) (US)
- Corresponding author
- Ling, Lei
- Venue
- Nature Communications
- Published
- 2017-05-16
- Volume
- 8
- Issue
- 1
- Pages
- 15433-15433
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5440856
- OpenAlex
- W2616559215
- Cited by
- 123
- References
- 62
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 12 · 2021: 19 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 5
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- NGM Biopharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- FGF19, hepatocellular carcinoma, IL-6/STAT3 signaling, non-cell-autonomous signaling, liver microenvironment, JAK inhibitors, anti-IL-6 antibody, bile acid metabolism, glucose metabolism, energy metabolism, hepatocarcinogenesis
- MeSH terms
- Dependovirus, Animals, Bile Acids and Salts, Body Composition, Energy Metabolism, Female, Fibroblast Growth Factors, Glucose, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Signal Transduction, Interleukin-6, Gene Expression Regulation, Neoplastic, Gene Deletion, Transgenes, Computational Biology, Gene Expression Profiling, STAT3 Transcription Factor, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-23, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-23 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.